Literature DB >> 3053465

Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue.

H Takasaki1, M A Tempero, E Uchida, M Büchler, M J Ness, D A Burnett, R S Metzgar, D Colcher, J Schlom, P M Pour.   

Abstract

Expression of tumor-associated glycoprotein (TAG-72) was examined by immunohistochemistry in pancreatic specimens from normal donors, and from patients with chronic pancreatitis and pancreatic cancer, and was compared with expression of CA 19-9 and DU-PAN-2. In the normal pancreas, TAG-72 was expressed in fewer ductal and ductular cells than were CA 19-9 (p less than 0.05) and DU-PAN-2 (p less than 0.01 and 0.001 respectively), whereas in chronic pancreatitis all 3 antigens were expressed in ductal cells but only CA 19-9 and DU-PAN-2 in ductular cells (p less than 0.001). In the specimens from normal pancreas and chronic pancreatitis cases, TAG-72 was localized in the Golgi region, whereas CA 19-9 and DU-PAN-2 showed diffuse cytoplasmic and glycocalyx patterns. In pancreatic cancer, although the rate of expression of all 3 antigens was similar, their cellular localization differed significantly: only TAG-72 was expressed in the Golgi region (p less than 0.001), whereas CA 19-9 showed mainly glycocalyx (p less than 0.05) and/or intra-luminal patterns (p less than 0.01) compared with that of the other 2 antigens. We conclude that, due to differences in expression of TAG-72 in benign versus malignant cells, the monoclonal antibody against TAG-72 (B72.3) may be suitable for radio-immunodetection or radio-immunotherapy of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053465     DOI: 10.1002/ijc.2910420508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Expression of human tumor-associated antigens in pancreatic cancer induced in Syrian hamsters.

Authors:  Y Takiyama; H Egami; P M Pour
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

2.  Establishment and characterization of a new, spontaneously immortalized, pancreatic ductal cell line from the Syrian golden hamster.

Authors:  T Takahashi; M P Moyer; M Cano; Q J Wang; T E Adrian; C P Mountjoy; W Sanger; H Sugiura; H Katoh; P M Pour
Journal:  Cell Tissue Res       Date:  1995-10       Impact factor: 5.249

3.  Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters.

Authors:  H Egami; T Tomioka; M Tempero; D Kay; P M Pour
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

4.  Aberrant acinar cell CA 19-9 expression and peri-insular acinar cell alterations in an adult human pancreas.

Authors:  Matthias Evert; Christiane Seiler; Frank Dombrowski
Journal:  Virchows Arch       Date:  2004-10-26       Impact factor: 4.064

5.  A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens.

Authors:  X Fu; F Guadagni; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

Review 6.  Biology of pancreatic cancer.

Authors:  G J Poston; J Gillespie; P J Guillou
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

7.  Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model.

Authors:  T H El-Metwally; M R Hussein; S Kh Abd-El-Ghaffar; M M Abo-El-Naga; A B Ulrich; P M Pour
Journal:  J Clin Pathol       Date:  2006-02-10       Impact factor: 3.411

8.  The patterns of coexpression of tumor-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer.

Authors:  I Toshkov; M Mogaki; K Kazakoff; P M Pour
Journal:  Int J Pancreatol       Date:  1994-04

9.  In Vivo Pretargeted Imaging of HER2 and TAG-72 Expression Using the HaloTag Enzyme.

Authors:  James C Knight; Michael Mosley; H Tetsuo Uyeda; Mei Cong; Frank Fan; Stephen Faulkner; Bart Cornelissen
Journal:  Mol Pharm       Date:  2017-06-08       Impact factor: 4.939

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.